Xilonix: Additional Phase III data

XBiotech reported additional data from a double-blind, European Phase III trial in 309 patients with symptomatic, refractory, metastatic colorectal cancer evaluating IV Xilonix every 2 weeks plus

Read the full 272 word article

User Sign In